Reduction of brain kynurenic acid improves cognitive function

Journal of Neuroscience

Volumn 34, Issue 32, 2014, Pages 10592-10602

  Kozak, Rouba ^a   Campbell, Brian M ^d   Strick, Christine A ^a   Horner, Weldon ^a   Hoffmann, William E ^a   Kiss, Tamas ^a   Chapin, Douglas S ^a   McGinnis, Dina ^a   Abbott, Amanda L ^b,c   Roberts, Brooke M ^b,c   Fonseca, Kari ^a   Guanowsky, Victor ^a   Young, Damon A ^a   Seymour, Patricia A ^a,e   Dounay, Amy ^a   Hajos, Mihaly ^b   Williams, Graham V ^b,c   Castner, Stacy A ^b,c  

^a PFIZER INC   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^d LUNDBECK RESEARCH USA   (United States)

^e Mnemosyne Pharmaceuticals Inc   (United States)

Author keywords

Cognition; KAT II; Kynurenic acid; L kynurenine; Schizophrenia; Working memory

Indexed keywords

COGNITION; KAT II; KYNURENIC ACID; L-KYNURENINE; SCHIZOPHRENIA; WORKING MEMORY;

ANIMALS; ATTENTION; BRAIN; COGNITION; ENZYME INHIBITORS; EVOKED POTENTIALS, AUDITORY; FEMALE; HIPPOCAMPUS; HUMANS; KYNURENIC ACID; MACACA MULATTA; MALE; MAZE LEARNING; MEMORY, SHORT-TERM; NEURONS; PYRAZOLES; RATS; RATS, LONG-EVANS; RATS, SPRAGUE-DAWLEY; SCHIZOPHRENIA; WAKEFULNESS;

EID: 84905674931     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.1107-14.2014     Document Type: Article

References (42)

1. Amori L, Wu HQ, Marinozzi M, Pellicciari R, Guidetti P, Schwarcz R (2009) Specific inhibition of kynurenate synthesis enhances extracellular dopamine levels in the rodent striatum. Neuroscience 159:196-203. CrossRef Medline
2. Baddeley A. (1992) Working memory. Science 255:556-559. CrossRef Medline
3. Baron B. M, Siegel BW, Harrison BL, Gross RS, Hawes C, Towers P (1996) [3H]MDL 105,519, a high-affinity radioligand for the N-methyl-Daspartate receptor-associated glycine recognition site. J Pharmacol Exp Ther 279:62-68. Medline
4. Carrillo-Mora P., Méndez-Cuesta LA, Pérez-De La Cruz V, Fortoul-van Der Goes T. I, Santamaría A (2010) Protective effect of systemic l-kynurenine and probenecid administration on behavioural and morphological alterations induced by toxic soluble amyloid beta (25-35) in rat hippocampus. Behav Brain Res 210:240-250. CrossRef Medline
5. Castner S. A, Goldman-Rakic PS (1999) Long-lasting psychotomimetic consequences of repeated low dose amphetamine exposure in rhesus monkeys. Neuropsychopharmacology 20:10-28. CrossRef Medline
6. Castner S. A, Smagin GN, Piser TM, Wang Y, Smith JS, Christian EP, Mrzljak L, Williams GV (2011) Immediate and sustained improvements in working memory following selective stimulation of alpha7 nicotinic acetylcholine receptors. Biol Psychiatry 69:12-18. CrossRef Medline
7. Chess A. C, Simoni MK, Alling TE, Bucci DJ (2007) Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophr Bull 33:797-804. CrossRef Medline
8. Chess A. C, Landers AM, Bucci DJ (2009) L-kynurenine treatment alters contextual fear conditioning and context discrimination but not cuespecific fear conditioning. Behav Brain Res 201:325-331. CrossRef Medline
9. Dounay A. B, Anderson M, Bechle BM, Campbell BM, Claffey MM, Evdokimov A, Evrard E, Fonseca KR, Gan X, Ghosh S, Hayward MM, Horner W, Kim J. Y, McAllister LA, Pandit J, Paradis V, Parikh VD, Reese MR, Rong S, Salafia M. A, et al (2012) Discovery of brain-penetrant, irreversible kynurenine aminotransferase II inhibitors for schizophrenia. ACS Med Chem Lett 3:187-192. CrossRef Medline
10. Erhardt S., Blennow K, Nordin C, Skogh E, Lindström LH, Engberg G (2001) Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett 313:96-98. CrossRef Medline
11. Gold J. M, Hahn B, Zhang WW, Robinson BM, Kappenman ES, Beck VM, Luck S. J (2010) Reduced capacity but spared precision and maintenance of working memory representations in schizophrenia. Arch Gen Psychiatry 67:570-577. CrossRef Medline
12. Goldman-Rakic P. S (1994) Working memory dysfunction in schizophrenia. J Neuropsychiatry Clin Neurosci 6:348-357. Medline
13. Hajós M. (2006) Targeting information-processing deficit in schizophrenia: a novel approach to psychotherapeutic drug discovery. Trends Pharmacol Sci 27:391-398. CrossRef Medline
14. Hajós M., Hoffmann WE, Kocsis B (2008) Activation of cannabinoid-1 receptors disrupts sensory gating and neuronal oscillation: relevance to schizophrenia. Biol Psychiatry 63:1075-1083. CrossRef Medline
15. Hilmas C., Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX (2001) The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci 21:7463-7473. Medline
16. Javitt D. C, Spencer KM, Thaker GK, Winterer G, Hajós M (2008) Neurophysiological biomarkers for drug development in schizophrenia. Nat Rev Drug Discov 7:68-83. CrossRef Medline
17. Justinova Z., Mascia P, Wu HQ, Secci ME, Redhi GH, Panlilio LV, Scherma M, Barnes C., Parashos A, Zara T, Fratta W, Solinas M, Pistis M, Bergman J, Kangas B. D, Ferré S, Tanda G, Schwarcz R, Goldberg SR (2013) Reducing cannabinoid abuse and preventing relapse by enhancing endogenous brain levels of kynurenic acid. Nat Neurosci 16:1652-1661. CrossRef Medline
18. Kalvass J. C, Maurer TS (2002) Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos 23:327-338. CrossRef Medline
19. Kiss T., Hoffmann WE, Scott L, Kawabe TT, Milici AJ, Nilsen EA, Hajós M (2011) Role of thalamic projection in NMDA receptor-induced disruption of cortical slow oscillation and short-term plasticity. Front Psychiatry 2:14. CrossRef Medline
20. Konradsson-Geuken A., Wu HQ, Gash CR, Alexander KS, Campbell A, Sozeri Y, Pellicciari R, Schwarcz R, Bruno JP (2010) Cortical kynurenic acid bi-directionally modulates prefrontal glutamate levels as assessed by microdialysis and rapid electrochemistry. Neuroscience 169:1848-1859. CrossRef Medline
21. Koshy Cherian A., Gritton H, Johnson DE, Young D, Kozak R, Sarter M (2014) A systemically available kynurenine aminotransferase II (KAT II) inhibitor restores nicotine-evoked glutamatergic activity in the cortex of rats. Neuropharmacology 82:41-48. CrossRef Medline
22. Levin E. D, Bettegowda C, Weaver T, Christopher NC (1998) Nicotine-dizocilpine interactions and working and reference memory performance of rats in the radial-arm-maze. Pharmacol Biochem Behav 61:335-340. CrossRef Medline
23. Linderholm K. R, Skogh E, Olsson SK, Dahl ML, Holtze M, Engberg G, Samuelsson M, Erhardt S (2012) Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bull 38:426-432. CrossRef Medline
24. Lopes C., Pereira EF, Wu HQ, Purushottamachar P, Njar V, Schwarcz R, Albuquerque E. X (2007) Competitive antagonism between the nicotinic allosteric potentiating ligand galantamine and kynurenic acid at alpha7* nicotinic receptors. J Pharmacol Exp Ther 322:48-58. CrossRef Medline
25. McGaughy J., Kaiser T, Sarter M (1996) Behavioral vigilance following infusions of 192 IgG-saporin into the basal forebrain: selectivity of the behavioral impairment and relation to cortical AChE-positive fiber density. Behav Neurosci 110:247-265. CrossRef Medline
26. Millan M. J (2002) N-methyl-D-aspartate receptor-coupled glycineB receptors in the pathogenesis and treatment of schizophrenia: a critical review. Curr Drug Targets CNS Neurol Disord 1:191-213. CrossRef Medline
27. Millan M. J (2005) N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives. Psychopharmacology (Berl) 179:30-53. CrossRef Medline
28. Mok M. H, Fricker AC, Weil A, Kew JN (2009) Electrophysiological characterisation of the actions of kynurenic acid at ligand-gated ion channels. Neuropharmacology 57:242-249. CrossRef Medline
29. Nilsson L. K, Linderholm KR, Engberg G, Paulson L, Blennow K, Lindström LH, Nordin C, Karanti A, Persson P, Erhardt S (2005) Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr Res 80:315-322. CrossRef Medline
30. Paxinos G., Watson C (1997) The rat brain in stereotaxic coordinates. San Diego: Academic.
31. Pocivavsek A., Wu HQ, Elmer GI, Bruno JP, Schwarcz R (2012) Pre-and postnatal exposure to kynurenine causes cognitive deficits in adulthood. Eur J Neurosci 35:1605-1612. CrossRef Medline
32. Potter M. C, Elmer GI, Bergeron R, Albuquerque EX, Guidetti P, Wu HQ, Schwarcz R. (2010) Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior. Neuropsychopharmacology 35:1734-1742. CrossRef Medline
33. Rassoulpour A., Wu HQ, Ferre S, Schwarcz R (2005) Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum. J Neurochem 93:762-765. CrossRef Medline
34. Roberts B. M, Seymour PA, Schmidt CJ, Williams GV, Castner SA (2010) Amelioration of ketamine-induced working memory deficits by dopamine D1 receptor agonists. Psychopharmacology (Berl) 210:407-418. CrossRef Medline
35. Schwarcz R., Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC (2001) Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 50:521-530. CrossRef Medline
36. Shepard P. D, Joy B, Clerkin L, Schwarcz R (2003) Micromolar brain levels of kynurenic acid are associated with a disruption of auditory sensory gating in the rat. Neuropsychopharmacology 28:1454-1462. CrossRef Medline
37. St Peters M., Demeter E, Lustig C, Bruno JP, Sarter M (2011) Enhanced control of attention by stimulating mesolimbic-corticopetal cholinergic circuitry. J Neurosci 31:9760-9771. CrossRef Medline
38. Strick C. A, Li C, Scott L, Harvey B, Hajós M, Steyn SJ, Piotrowski MA, James L. C, Downs JT, Rago B, Becker SL, El-Kattan A, Xu Y, Ganong AH, Tingley FD 3rd, Ramirez AD, Seymour PA, Guanowsky V, Majchrzak MJ, Fox CB, et al (2011) Modulation of NMDA receptor function of D-amino acid oxidase in rodent brain. Neuropharmacology 61:1001-1015. CrossRef Medline
39. Ward L., Mason SE, Abraham WC (1990) Effects of the NMDA antagonists CPP and MK801 in radial arm maze performance in rats. Pharmacol Biochem Behav 35:785-790. CrossRef Medline
40. Watson G. B, Hood WF, Monahan JM, Lanthorn TH (1988) Kynurenate antagonises actions of NMDA through a glycine-sensitive receptor. Neurosci Res Commun 2:169-174.
41. Wu H. Q, Lee SC, Schwarcz R (2000) Systemic administration of 4-chlorokynurenine prevents quinolinate neurotoxicity in the rat hippocampus. Eur J Pharmacol 390:267-274. CrossRef Medline
42. Wu H. Q, Pereira EF, Bruno JP, Pellicciari R, Albuquerque EX, Schwarcz R (2010) The astrocyte-derived alpha7 nicotinic receptor antagonist kynurenic acid controls extracellular glutamate levels in the prefrontal cortex. J Mol Neurosci 40:204-210. CrossRef Medline